Clinical Research Directory
Browse clinical research sites, groups, and studies.
Management of CSDH With or Without EMMA- a Randomized Control Trial
Sponsor: University of Manitoba
Summary
EMMA-Can is a prospective randomized open-label, blinded end point (PROBE) study, that will assess the recurrence risk and safety of embolization of the middle meningeal (EMMA) when added to standard of care treatment (surgical drainage) of chronic subdural hematoma (CSDH) compared to surgical treatment alone.
Official title: Management of Chronic Subdural Hematoma With or Without Embolization of Middle Meningeal Artery in Canada (EMMA-Can)- A Randomized Control Trial.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
192
Start Date
2021-08-01
Completion Date
2026-03-31
Last Updated
2025-12-15
Healthy Volunteers
No
Conditions
Interventions
Embolization of the Middle Meningeal Artery
EMMA is performed inside of the blood vessels where tiny catheters are used to deliver a liquid embolic agent (Onyx) to block small blood vessels supplying the brain coverings.
Locations (1)
University of Manitoba
Winnipeg, Manitoba, Canada